TRASTUZUMABE DERUXTECANA/PROs T-DXd
OC Oncoclínicas RJ
EVALUATION OF QUALITY OF LIFE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER TREATED WITH TRASTUZUMAB DERUXTECAN IN THE ONCOCLINIS GROUP
Biomarker: HER+
Center
OC Oncoclínicas RJ
Principal investigator
Diogo Rodrigues
Telephone
(21) 97138-0225 e (21) 2127-0281Inclusion criteria
Female or male patients with HER+ metastatic malignancy of the breast who will start treatment with T-DXd; Age greater than 18 years.
Exclusion criteria
Use of other concomitant antineoplastic therapies;
Patients for whom the physician responsible for prescribing T-DXd is from an institution other than the Oncoclínicas Group.
Coordinator(s)
Tamires Almeida
Clinical research
Check out more information about Grupo Oncoclínicas' clinical research program.
Learn more
